Dermatomyositis Treatment Guidelines

Initial Treatment and Management

• The American College of Rheumatology recommends starting oral prednisolone at 1-2 mg/kg/day (maximum 60-80 mg/day) combined with methotrexate 15-20 mg/m² weekly for the treatment of dermatomyositis 1, 2
• Administer methotrexate subcutaneously rather than orally for superior absorption 1, 2
• For severe presentations with profound weakness or major organ involvement, use high-dose intravenous methylprednisolone before transitioning to oral therapy 2

Essential Adjunctive Measures

• Provide rigorous sun protection to prevent photosensitive rash exacerbations 1, 2
• Prescribe calcium and vitamin D supplementation to prevent corticosteroid-induced osteoporosis 1, 2
• Initiate a supervised physiotherapy program to restore muscle strength during remission 1, 2

Treatment Algorithm Based on Response

• If clinical improvement occurs, begin tapering corticosteroids while maintaining methotrexate 1, 2
• Continue monitoring muscle strength using validated measures (Manual Muscle Test, Childhood Myositis Assessment Scale) 1

Management of Inadequate Response or Intolerance

• Switch to mycophenolate mofetil or cyclosporine A as alternative DMARDs for methotrexate intolerance 1, 2
• Add intravenous immunoglobulin (IVIG) for inadequate response despite adherence, which shows particular efficacy for cutaneous manifestations 1, 2

Management of Refractory Disease

• Consider rituximab for refractory cases, but counsel patients that clinical response may take up to 26 weeks 1, 2
• Anti-TNF therapies (infliximab or adalimumab preferred over etanercept) may be considered 1

Critical Monitoring Requirements

• Muscle strength evaluation using validated measures 1
• Cardiac evaluation with troponin to assess for myocardial involvement 3
• Laboratory monitoring: CK, transaminases (AST, ALT), LDH, aldolase, ESR, CRP 1, 3

Special Considerations

• Use corticosteroids 2 mg/kg/day up to maximum 60 mg/day with subcutaneous methotrexate 15 mg/m² weekly for juvenile dermatomyositis 2
• Monitor vigilantly for calcinosis cutis, cutaneous vasculitis, and gastrointestinal vasculopathy in juvenile dermatomyositis 2

Common Pitfalls to Avoid

• Do not use oral methotrexate when subcutaneous administration is feasible due to inferior absorption 1, 2
• Do not delay adding methotrexate to corticosteroids—dual therapy from the outset improves outcomes 1, 2
• Do not use etanercept if anti-TNF therapy is considered—infliximab or adalimumab are preferred 1